# EGF Ointment for Erlotinib Skin Lesion

> **NCT01593995** · PHASE2 · COMPLETED · sponsor: **Dong-A University Hospital** · enrollment: 52 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** Epidermal growth factor (EGF) ointment

## Key facts

- **NCT ID:** NCT01593995
- **Lead sponsor:** Dong-A University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-12
- **Final completion:** 2014-10
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01593995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01593995, "EGF Ointment for Erlotinib Skin Lesion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01593995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*